

Figure S1. 1H NMR of the PLEGPs. (A) Poly[bis(ε-Lys)Glut-PEG]; (B) $PLEGP_{600}$; (C) $PLEGP_{1800}$; (D) $PLEGP_{10k}$.



Figure S2. Zeta potential of $PLEGP_{600}$, $PLEGP_{1800}$, and $PLEGP_{10k}$.



Figure S3. Pharmacokinetic profiles of free siRNA and the siRNA/PLEGP$_{1800}$ nanocomplex in mice. Cy5-labeled free siRNA or siRNA/PLEGP$_{1800}$ nanocomplex were injected via tail vein at a dose of 1.5 mg siRNA/kg. The results are presented as the mean ± SD (n=3).



Figure S4. Western blots of VEGF expressions in tumor tissues from the mice treated with the VEGF siRNA/PLEGP$_{1800}$ nanocomplex.



Figure S5. Microvessel density in tumor tissues. Immunohistochemical analysis was performed to determine the microvessel density in tumor tissues using a mouse anti-human CD31 antibody. The densities were normalized to the saline group and presented as the percentage mean ± SD (n=3). (** $P < 0.01$)